查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1918115

鴉片類藥物使用疾患治療市場－2026-2031年預測

Opioid Use Disorder Treatment Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

鴉片類藥物使用障礙治療市場預計將從 2025 年的 75.88 億美元成長到 2031 年的 115.45 億美元，複合年成長率為 7.25%。

由於鴉片類藥物成癮帶來的臨床和社會負擔日益加重，包括強迫性使用、高復發風險和潛在的致命過量用藥，鴉片類藥物使用障礙（OUD）治療市場正在穩步擴張。藥物輔助治療（MOUD）－包括美沙酮、Buprenornhine和納曲酮－是實證治療的基礎，而行為諮商和同儕支持模式則作為重要的輔助手段，有助於提高治療依從性和改善長期治療效果。

關鍵需求促進因素源自於鴉片類藥物在治療癌症、心血管疾病、整形外科疾病、術後復健和創傷等引起的慢性疼痛方面的廣泛醫療用途。即使臨床上確有指徵，長期用藥也往往會導致成癮，並在減重或停藥後出現戒斷症候群，從而維持著龐大且不斷成長的患者群體。

美國的結構性改革預計將顯著擴大藥物輔助治療（MOUD）的覆蓋範圍，從而在整個預測期內加速市場成長。 DATA-2000豁免條款的廢除以及Buprenornhine處方患者人數限制的取消，消除了長期存在的障礙，使更多醫療保健專業人員能夠啟動和維持治療。聯邦醫療保險（Medicare）和各州醫療補助計劃（Medicaid）擴大了對綜合鴉片類藥物治療項目（OTP）的覆蓋範圍——對包括美沙酮給藥、中毒檢測、護理和諮詢在內的綜合服務（代碼H0020）進行報銷——進一步降低了經濟障礙。值得注意的是，醫療補助計劃已經涵蓋了美國約40%非老年鴉片類藥物使用障礙（OUD）患者的治療費用。

實證心理社會介入措施的整合仍在不斷發展中。戒毒互助會、酒精成癮、動機增強療法和結構化諮詢正擴大被納入住院和門診治療方案中，以幫助患者重新評估其鴉片類藥物使用情況，加強復發預防技能，並建立以康復為導向的行為模式。

由於慢性疼痛疾病的高發生率、惡性及非惡性疼痛的鴉片類藥物處方率高，以及主要生產商在北美地區的集中商業性，預計北美將繼續保持其市場領先地位。像Indivior這樣的公司的大部分收入都來自美國市場，這反映了該地區沉重的疾病負擔和有利的報銷趨勢。

創新持續聚焦於研發能提高病患依從性、減少非法分銷並簡化給藥方式的製劑。 2023年5月，一項具有里程碑意義的監管進展出現：美國食品藥物管理局（FDA）批准了BRIXADI（Buprenornhine）的修訂版新藥申請。 BRIXADI是一種Buprenornhine緩釋皮下注射（每週一次或每月一次），用於治療中度至重度鴉片類藥物使用疾患（OUD）。長效Buprenornhine注射劑的核准和即將上市核准將代表治療模式的轉變，尤其對於那些難以堅持口服藥物的患者群體而言。

競爭的焦點在於下一代藥物遞送系統、聯合藥物療法以及用於增強行為矯正的數位化治療輔助。包括Braeburn Pharmaceuticals在內的領先研發企業正持續開發候選藥物，以滿足誘導期、穩定期和維持期尚未滿足的醫療需求。

總之，在不可逆轉的放鬆管制、公共醫療保險對鴉片類藥物治療項目的全面覆蓋以及醫療用鴉片類藥物暴露帶來的持續臨床需求的推動下，鴉片類藥物使用障礙（OUD）治療領域正蓄勢待發，準備持續擴張。北美在市場規模和治療創新方面繼續保持主導，而像BRIXADI這樣的長效注射用Buprenornhine製劑代表了近期最顯著的進展，為中重度鴉片類藥物使用障礙患者提供了更多安全、有效且易於獲得的藥物輔助治療（MOUD）選擇。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2021-2025 年）和預測資料（2026-2031 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

5. 依治療方法的鴉片類藥物使用障礙治療市場

  • 介紹
  • 藥物治療
    • Buprenornhine
    • 美沙酮
    • 納曲酮
  • 諮商與行為療法

6. 依給藥途徑分類的鴉片類藥物使用障礙治療市場

  • 介紹
  • 口服
  • 注射

7. 按最終用戶分類的鴉片類藥物使用障礙治療市場

  • 介紹
  • 復健中心
  • 專科診所
  • 其他

8. 按地區分類的鴉片類藥物使用障礙治療市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章：競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第10章：公司簡介

  • Indivior Plc
  • Alkermes Plc
  • Orexo AB
  • Titan Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Camurus
  • Collegium Pharmaceuticals

第11章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061615587

The opioid use disorder treatment market, at a 7.25% CAGR, is anticipated to reach USD 11.545 billion in 2031 from USD 7.588 billion in 2025.

The opioid use disorder (OUD) treatment market is expanding steadily, propelled by the escalating clinical and societal burden of opioid dependence characterized by compulsive use, high relapse risk, and potential for fatal overdose. Medication for opioid use disorder (MOUD) - methadone, buprenorphine, and naltrexone - constitutes the evidence-based foundation of therapy, with behavioral counseling and peer-support models serving as critical adjuncts that improve retention and long-term outcomes.

Primary demand drivers remain rooted in the widespread medical use of opioids for chronic pain associated with cancer, cardiovascular disease, orthopedic conditions, post-surgical recovery, and trauma. Prolonged exposure, even when clinically indicated, frequently transitions legitimate prescribing into dependence and withdrawal syndromes upon dose reduction or cessation, sustaining a large and growing treatment-eligible population.

Structural reforms in the United States have significantly broadened access to MOUD and are expected to accelerate market growth throughout the forecast period. The elimination of the DATA-2000 waiver and removal of patient caps on buprenorphine prescribing have removed longstanding barriers, enabling a far wider range of practitioners to initiate and maintain therapy. Expanded Medicare and state Medicaid coverage of comprehensive opioid treatment programs (OTPs) - reimbursed through bundled services under code H0020 that include methadone administration, toxicology screening, nursing, and counseling - further lowers financial hurdles. Notably, Medicaid already finances care for approximately 40% of non-elderly adults with OUD in the U.S.

Integration of evidence-based psychosocial interventions continues to gain traction. Narcotics Anonymous, Alcoholics Anonymous, motivational enhancement, and structured counseling are increasingly embedded within inpatient and outpatient programs, helping patients reframe opioid use, strengthen relapse-prevention skills, and build recovery-oriented behavioral repertoires.

North America is projected to maintain clear market leadership, driven by high prevalence of chronic pain conditions, elevated rates of opioid prescribing for both malignant and non-malignant pain, and concentrated commercial presence of major manufacturers. Companies such as Indivior derive the majority of revenue from the U.S. market, reflecting both disease burden and favorable reimbursement dynamics.

Innovation remains focused on formulations that enhance adherence, reduce diversion, and simplify administration. A landmark regulatory advancement occurred in May 2023 when the FDA accepted Braeburn's revised New Drug Application for BRIXADI (buprenorphine) extended-release subcutaneous injection (weekly and monthly dosing) for moderate to severe OUD. Approval and subsequent launch of long-acting injectable buprenorphine formulations are anticipated to shift treatment paradigms, particularly in populations with poor oral medication adherence.

Competitive activity centers on next-generation delivery systems, combination pharmacotherapies, and digital therapeutic adjuncts designed to reinforce behavioral change. Leading developers, including Braeburn Pharmaceuticals, continue to advance candidates that address unmet needs in induction, stabilization, and maintenance phases.

In conclusion, the OUD treatment sector is poised for sustained expansion, supported by irreversible regulatory liberalization, comprehensive public insurance coverage of OTP services, and persistent clinical need generated by medical opioid exposure. North America will continue to dominate both in market size and therapeutic innovation, with long-acting injectable buprenorphine formulations such as BRIXADI representing the most significant recent advancement in expanding safe, effective, and accessible MOUD options for patients with moderate to severe opioid use disorder.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Opioid Use Disorder Treatment Market Segmentation:

BY TREATMENT TYPE

  • Medication
  • Buprenorphine
  • Methadone
  • Naltrexone
  • Counseling & Behavioral Therapies

BY ROUTE OF ADMINISTRATION

  • Oral
  • Injectable

BY END-USER

  • Rehabilitation Centers
  • Specialized Clinics
  • Others

BY GEOGRAPHY

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. OPIOID USE DISORDER TREATMENT MARKET BY TREATMENT TYPE

  • 5.1. Introduction
  • 5.2. Medication
    • 5.2.1. Buprenorphine
    • 5.2.2. Methadone
    • 5.2.3. Naltrexone
  • 5.3. Counseling & Behavioral Therapies

6. OPIOID USE DISORDER TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injectable

7. OPIOID USE DISORDER TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Rehabilitation Centers
  • 7.3. Specialized Clinics
  • 7.4. Others

8. OPIOID USE DISORDER TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Indivior Plc
  • 10.2. Alkermes Plc
  • 10.3. Orexo AB
  • 10.4. Titan Pharmaceuticals Inc.
  • 10.5. Teva Pharmaceutical Industries Ltd.
  • 10.6. Mallinckrodt Pharmaceuticals
  • 10.7. Pfizer Inc.
  • 10.8. Hikma Pharmaceuticals PLC
  • 10.9. Camurus
  • 10.10. Collegium Pharmaceuticals

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations